All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Insulin-Like Growth Factor 1, Long R3
For educational and research purposes only. Not medical advice.
IGF-1 LR3 is the most potent growth factor peptide available. Unique for promoting muscle hyperplasia (new cells). High risk profile — potent hypoglycemic effects and theoretical cancer promotion. Used primarily in performance contexts with careful monitoring.
Best Time
Post-workout or morning
Method
subcutaneous
Frequency
Daily
Half-life
~20-30 hours
Cycle Length
4-6 weeks max
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
IGF-1 LR3 drives systemic muscle protein synthesis while MGF (mechano growth factor) activates local satellite cells at the site of muscle damage. Used sequentially — MGF post-workout, IGF-1 LR3 later.
communityFollistatin removes the myostatin brake on muscle growth while IGF-1 LR3 provides the anabolic signal. Complementary push-pull mechanism for hypertrophy. Theoretical synergy; no clinical combination data.
theoreticalInternational journal of molecular sciences 23 (23) · 2022-11-29
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 34 (8) :10041-10055 · 2020-08-01
American journal of physiology. Endocrinology and metabolism 320 (6) :E1138-E1147 · 2021-06-01
American journal of physiology. Endocrinology and metabolism 328 (1) :E116-E125 · 2025-01-01
Journal of developmental origins of health and disease 14 (3) :353-361 · 2023-06-01
Mechanism of Action
Modified IGF-1 with an arginine substitution and 13-amino-acid extension. Reduced IGF-binding protein affinity extends half-life and increases bioavailability. Promotes muscle hyperplasia, not just hypertrophy.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.